SEC Form 4 · accession 0001214659-19-001750
Aquestive Therapeutics, Inc. · AQST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith J Kendall
Officer — CEO and President · Director
Period of report
Feb 28, 2019
Accepted (ET)
Mar 4, 2019 · 4:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001398733
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $8.05 | Feb 28, 2019 | A | 325,000 | A | — | Feb 28, 2029 | Common Stock | 325,000 | 325,000 | D |
Explanation of responses
- F1The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries.